Takeda Pharmaceutical Company Limited

Takeda reported Q1 FY26 revenue of JPY 1.22 trillion, up 10.2% year over year on an actual FX basis but down 0.5% at constant exchange rates. Core operating profit was JPY 358.9 billion, up 11.5% actual FX and down 0.5% at CER, while core EPS was JPY 154, down 11.8% at CER; reported operating profit was JPY 201.4 billion and reported EPS was JPY 72. Management said operating cash flow was lower than last year due to working capital changes tied to trade receivables factoring, and adjusted free cash flow also reflected a USD 200 million payment to Protagonist after Takeda opted out of the rusfertide co-promotion agreement. Full-year FY26 guidance was unchanged, including free cash flow of JPY 650 billion to JPY 750 billion, and management said the gross margin rate was maintained at 65% for the full year. On the revenue bridge, core in-line brands grew 2.3% at CER, ENTYVIO grew 4% at CER, and the new-launch category grew 22.6% at CER.

Julie Kim framed the quarter as a solid start to FY26 and repeatedly emphasized that Takeda is executing its two-horizon strategy. Her message was that Horizon One is about transformation, launch preparation, and protecting the core while funding future growth; Horizon Two is the period of accelerated growth, structural margin expansion, and higher ROE. She highlighted ORZEYFUL, rusfertide, and zasocitinib as the key near-term launch drivers and said Takeda is building the commercial and operational foundation now so these medicines can reach patients quickly.

Milano Furuta said Q1 was on track to full-year guidance, with revenue of JPY 1.22 trillion, core operating profit of JPY 358.9 billion, and core EPS of JPY 154. He explained that core revenue weakness was mainly due to LOE and mature-product headwinds, including generic erosion in VYVANSE, while core in-line brands and new launches offset much of that pressure. On margins, he said gross profit benefited from favorable FX and a one-time divestiture-related milestone, but the full-year effect of that item is negligible; he also said the company is maintaining its 65% full-year gross margin outlook. He reiterated the JPY 650 billion to JPY 750 billion free-cash-flow target and said Q1 cash flow was affected by factoring-related working-capital moves and the USD 200 million Protagonist payment.

Analysts focused on gross margin, ORZEYFUL commercialization, TAK-360, ENTYVIO durability and biosimilar timing, rusfertide pricing, and mezagitamab’s outlook. Management said the Q1 gross-margin lift was mostly due to favorable FX in PDT and a small one-time divestiture-related technology-transfer milestone, while the product-mix effect was essentially neutral. On ORZEYFUL, Julie Kim said Takeda expects it to be used as monotherapy, with initial growth coming from already-diagnosed NT1 patients on therapy and later from improved diagnosis; she also said pricing will aim to balance value recognition with fast access. For ENTYVIO, she said U.S. demand is still growing despite pricing/mix and inventory effects, and Takeda still expects U.S. biosimilar entry to remain roughly 3 to 5 years away due to litigation. Andy Plump said TAK-360 is being studied in NT1, NT2, and idiopathic hypersomnia to better understand orexin biology and dosing, and said zasocitinib’s UC and Crohn’s data should read out by fiscal year-end, though disclosure timing is still being decided.